
Supplementary Table 1: Intraocular inflammation cases in brolucizumab 6 mg-treated Japanese eyes with PCV.

Pt #	Adverse Event as reported (preferred term)	AE start (day)	Duration (days)	Other adverse events as reported (preferred term)	Treatment for IOI (Days administered)	Action taken with study drug	Latest BCVA vs BL	As noted by the SRC		
								Inflamma- tion	Vasculitis	Occlusive
1	Iritis	29	29	-	No medications for IOI administered	Patient continued on treatment and completed study	50 (+10L)	Yes probable	No	No
2	Uveitis	51	287	-	Top Betamethasone (85-106; 183-309), Top Fluorometholone (106-168), IO Dexamethasone (184), IO Triamcinolone (148 and 192)	Drug withdrawn (last injection Day 120)	75 (+16L)	Yes	Yes	No
3	Iritis	50	183	Cataract aggravated (Cataract)	Top Levofloxacin (54-63), Top Bromfenac (57-81; 84-141), Top Betamethasone (84- 141), Subconj Dexamethasone (92), Top Aciclovir (100-172)	Drug withdrawn (last injection Day 57)	52 (-4L)	Yes	Yes	No
4	Uveitis	12	214	Branch retinal artery occlusion (Retinal artery occlusion)	Top Moxifloxacin (26- 33), Top Betamethasone (26- 81; 141-166), Top Fluorometholone (82- 141, 167-194; 226- 365), Top Bromfenac (195-225)	continued on treatment but later withdrew	80 (+18L)	Yes	Yes	Yes
5	Anterior chamber inflammation	17	21	-	Top Moxifloxacin (17- 37)	Patient continued on treatment and completed study	87 (+19L)	Yes probable	Yes probable	Yes probable
6	Retinal perivascular sheathing	167	Ongoing at last report (Day 197)	-	No medication administered	Drug withdrawn (last injection Day 139)	70 (0L)	Yes	Yes	No

Medical Dictionary for Regulatory Activities Version 20.1 has been used for the reporting of adverse events. AE, adverse event; BCVA, best corrected visual acuity; BL, baseline; IOI, intraocular inflammation; L, letters; SRC, Safety Review Committee; Top, topical.

Supplementary Figure S1: HAWK study design



q8w, every 8 weeks; q12w, every 12 weeks.